Becker's Healthcare December 4, 2024
Alexandra Murphy

CMS has reached agreements with bluebird bio and Vertex Pharmaceuticals for their FDA-approved gene therapies for sickle cell disease — Casgevy and Lyfgenia, respectively.

Under the Cell and Gene Therapy Access Model, CMS will tie payments for the therapies to their effectiveness in improving health outcomes for Medicaid recipients, according to a Dec. 4 news release from the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicaid, Payment Models, Pharma / Biotech, Value Based
Related Articles:
After slow start, ACA enrollment takes off
CMS says record 16.6 million have signed up for Jan. 1 Marketplace coverage
How has U.S. Spending on Health Care Changed Over Time?
CMS Launches New Program for Mental Health, OUD Treatment
CMS ending VBID model due to high costs

Share This Article